Evolent Health, Inc. (EVH) Guidance & Earnings Results

On 2026-08-06 Evolent Health, Inc. raised guidance: "FY26 revenue raised to $2.6-2.7B; FY26 Adjusted EBITDA tightened to $120-135M; FY27 revenue growth >25%, FY27 Adjusted EBITDA midpoint at or above…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

EVHEvolent Health, Inc.Follow EVH — free

Health Information Services · Healthcare

—

Price chart with a free account

Market cap: 542.7M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	FY26 revenue raised to $2.6-2.7B; FY26 Adjusted EBITDA tightened to $120-135M; FY27 revenue growth >25%, FY27 Adjusted EBITDA midpoint at or above $150M · full year
7 May 26	Reaffirmed	FY2026 revenue $2.4B-$2.6B; Adjusted EBITDA $110M-$140M · full year
24 Feb 26	Raised	2026 revenue growth forecast approximately 30%.
6 Nov 25	Reaffirmed	Preliminary 2026 revenue forecast $2.5B · full year
7 Aug 25	Mixed	Q3 2025 revenue $460-480M, adjusted EBITDA $34-42M; FY2025 revenue $1.85-1.88B (lowered), adjusted EBITDA $140-165M (raised). · full year

Evolent Health, Inc. — questions

What guidance did Evolent Health, Inc. give?: On 2026-08-06: "FY26 revenue raised to $2.6-2.7B; FY26 Adjusted EBITDA tightened to $120-135M; FY27 revenue growth >25%, FY27 Adjusted EBITDA midpoint at or above $150M"
When does Evolent Health, Inc. report earnings?: Evolent Health, Inc.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Evolent Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.